Zacks Research Has Bearish Forecast for Perrigo Q3 Earnings

Perrigo Company plc (NYSE:PRGO) – Stock analysts at Zacks Research reduced their Q3 2026 earnings estimates for Perrigo in a research report issued on Wednesday, August 26th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.59 per share for the quarter, down from their prior estimate of $0.64. The consensus estimate for Perrigo’s current full-year earnings is $2.20 per share. Zacks Research also issued estimates for Perrigo’s Q4 2026 earnings at $0.64 EPS, FY2026 earnings at $2.16 EPS, Q1 2027 earnings at $0.47 EPS, Q2 2027 earnings at $0.47 EPS, Q3 2027 earnings at $0.52 EPS, Q4 2027 earnings at $0.84 EPS, FY2027 earnings at $2.29 EPS, Q2 2028 earnings at $0.67 EPS and FY2028 earnings at $2.70 EPS.

Several other analysts have also issued reports on PRGO. Weiss Ratings upgraded Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. Wall Street Zen upgraded Perrigo from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Perrigo has an average rating of “Hold” and an average price target of $19.33.

Perrigo Trading Up 2.0%

Perrigo stock opened at $14.77 on Thursday. The company’s fifty day simple moving average is $11.31 and its 200-day simple moving average is $11.42. The company has a quick ratio of 1.32, a current ratio of 2.32 and a debt-to-equity ratio of 1.31. Perrigo has a 12 month low of $9.23 and a 12 month high of $24.04. The stock has a market cap of $2.05 billion, a P/E ratio of -1.18, a P/E/G ratio of 1.65 and a beta of 0.51.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.11. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the business earned ($0.06) EPS. The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Institutional Investors Weigh In On Perrigo

Institutional investors and hedge funds have recently modified their holdings of the business. Amundi increased its position in Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after buying an additional 556 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Perrigo by 126.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after acquiring an additional 647,982 shares in the last quarter. United Services Automobile Association bought a new stake in shares of Perrigo during the 1st quarter worth about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Perrigo by 6.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after acquiring an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be paid a dividend of $0.29 per share. The ex-dividend date is Friday, August 28th. This represents a $1.16 annualized dividend and a dividend yield of 7.9%. Perrigo’s dividend payout ratio is -9.27%.

Key Stories Impacting Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Zacks raised Perrigo’s FY2026 EPS estimate to $2.16 from $2.10, bringing it closer to the broader consensus estimate of $2.20. The firm also increased its Q4 2027 forecast to $0.84 from $0.72, while projecting FY2027 and FY2028 EPS of $2.29 and $2.70, respectively.
• Neutral Sentiment: A Zacks value-investing comparison examined whether Perrigo or Neogen offers the better value opportunity. The article may support investor interest in PRGO, but it does not represent a new corporate development or a clear change in the company’s outlook. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Another Zacks article focused on whether value investors should buy Perrigo, highlighting the firm’s emphasis on earnings revisions, valuation, growth and momentum factors rather than announcing a new recommendation or company-specific catalyst. Should Value Investors Buy Perrigo Stock?
• Negative Sentiment: Zacks lowered several important forecasts: Q3 2026 EPS to $0.59 from $0.64, Q4 2026 to $0.64 from $0.72, Q1 2027 to $0.47 from $0.60, Q2 2027 to $0.47 from $0.58, Q3 2027 to $0.52 from $0.60, and FY2027 to $2.29 from $2.50. FY2028 was also trimmed slightly to $2.70 from $2.72.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.